Author

Tatiana V. Shelekhova

Observed names: T V Shelekhova, T. Shelekhova, T. V. Shelehova, T. V. Shelekhova, T.V. Shelekhova, Tatiana Shelekhova, Tatyana V. Shelekhova, Т. V. Shelekhova, Т.В. Шелехова

Institutions: Ministry of Health of the Russian Federation, Saratov State Medical University

Observed institutions: Saratov State University, National and Kapodistrian University of Athens, Navarre Institute of Health Research, Ministry of Health of the Russian Federation, Saratov State Medical University, Instituto de Investigación Biomédica de Salamanca, Clinica Universidad de Navarra, University of Bologna

ORCID: 0000-0002-4737-7695

Observed ORCID: 0000-0002-4737-7695

OpenAlex ID: A5068614681

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

2017 · María-Victoria Mateos, Meletios A. Dimopoulos, et al. · New England Journal of Medicine · 989

PDF

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

2014 · Jesús F San-Miguel, Vânia T M Hungria, et al. · The Lancet Oncology · 792

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

2019 · Maria-Victoria Mateos, Michele Cavo, et al. · The Lancet · 444

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

2020 · Jacob P Laubach, Fredrik Schjesvold, et al. · The Lancet Oncology · 69

The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty

2018 · Dmitriy Alekseevich Sychev, Alexander Levanov, et al. · Pharmacogenomics and Personalized Medicine · 62

PDF

Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML.

2011 · X. G. Thomas, A. Dmoszynska, et al. · Journal of Clinical Oncology · 29

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone

2019 · Maria-Victoria Mateos, Michele Cavo, et al. · Blood · 25

2021 · Stefan Knop, Maria-Victoria Mateos, et al. · BMC Cancer · 24

PDF

One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone

2018 · Meletios A Dimopoulos, Maria-Victoria Mateos, et al. · Blood · 22

Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,

2011 · Jesús F. San-Miguel, Vânia Tietsche de Moraes Hungria, et al. · Blood · 22

Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE)

2017 · Maria-Victoria Mateos, Meletios A. Dimopoulos, et al. · Blood · 20

Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study

2022 · Maria-Victoria Mateos, Jesús San-Miguel, et al. · Blood · 18

Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

2020 · Xavier Leleu, Meral Beksac, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 16

PDF

Current trends and challenges in the mitoxantrone measuring in biofluids and new pharmaceutical systems

2023 · Olga A. Goryacheva, Olga A. Goryacheva, et al. · TrAC Trends in Analytical Chemistry · 14

The relationship between oxidative stress and cytogenetic abnormalities in B-cell chronic lymphocytic leukemia

2020 · Tatiana Zhevak, Tatiana Shelekhova, et al. · Experimental and Molecular Pathology · 10

Problems of using personal protective equipment in modern conditions

2023 · Alexey D. Trubetskov, Margarita N. Makhonko, et al. · Russian Journal of Occupational Health and Industrial Ecology · 6

PDF

Bleeding rate reduction in children with hemophilia A and inhibitors treated with emicizumab in the real-world clinical setting

2022 · P. А. Zharkov, K. A. Voronin, et al. · Pediatric Hematology/Oncology and Immunopathology · 6

PDF

New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants

2020 · K. B. Mirzaev, D. V. Ivashchenko, et al. · Rational Pharmacotherapy in Cardiology · 6

Comparison of the clinical benefits of second-line drugs modifying the course of multiple sclerosis

2020 · M.V. Zhuravleva, M.V. Davydovskaya, et al. · S S Korsakov Journal of Neurology and Psychiatry · 6

Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases who receive cytotoxic therapy: results of LEGERITY, the second interim analysis of multicenter retrospective-and-prospective observational post-marketing study

2022 · Ekaterina S. Nesterova, Aleksandra F. Saydullaeva, et al. · Journal of Modern Oncology · 5

PDF

Impact of Abcb1 and Ces1 Genetic Polymorphisms on Trough Steady-state Dabigatran Concentrations in Patients After Endoprosthesis of Knife Join

2018 · D. A. Sychev, A. N. Levanov, et al. · Aterotromboz = Atherothrombosis · 5

PDF

Multiple Myeloma in Russia (First Results of the Registration Trial)

2017 · Л. П. Менделеева, Maxim Solovev, et al. · Blood · 5

Multiple myeloma: response to treatment and survival of patients according to the interim analysis of the Russian observational, retrospective-prospective, multicenter cohort study (MULTISPECT)

2022 · Vadim V. Ptushkin, Michail A. Kunst, et al. · Terapevticheskii arkhiv · 4

PDF

Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study

2020 · Jacob P. Laubach, Fredrik Schjesvold, et al. · Blood · 4

Interim Results of Epidemiological Study of Idiopathic Thrombocytopenic Purpura in Adults in the Russian Federation: Intermediate Results

2019 · A. L. Melikyan, E. K. Egorova, et al. · Гематология и трансфузиология · 4

PDF

Works count: 61

Citation count: 2,634

H-index: 14

I10-index: 15